VALNEVA to Present at the 17th World Vaccine Congress in Washington D.C.
10 Avril 2017 - 07:01AM
Valneva to Present at the 17th World
Vaccine Congress in Washington D.C.
Lyon (France), April 10, 2017 - Valneva
SE ("Valneva" or "the Company"), a leading pure play vaccine
company, announced today that it will be holding two presentations
on Lyme disease and mosquito-transmitted diseases on April 11, 2017
at the 17th World Vaccine Congress in Washington DC. Over 600
vaccine specialists will converge to the event.
Valneva's CEO, Thomas Lingelbach, will focus on
the development of a novel vaccine for protection against Lyme
disease, the most common infection following an insect bite in the
US. The Centers for Disease Control (CDC) estimates that 300,000
Americans[1] contract Lyme disease each year, calling it "a major
US public health problem". The presentation will include an update
on Valneva's development strategy for its Lyme disease vaccine VLA
15 which entered Phase I clinical trial in the US and Europe at the
beginning of the year. Pre-clinical data showed that VLA 15 has the
potential for protection against the majority of Borrelia species
pathogenic for humans[2].
Valneva will also present on vaccine development
against emerging mosquito-transmitted diseases, including its
vaccine candidates against diseases caused by Zika-, Chikungunya-
and Yellow fever- virus infections, building on the key
competencies it has developed from its successful bench to market
development of its Japanese Encephalitis vaccine.
Thomas Lingelbach, President and CEO and
Franck Grimaud, Deputy CEO of Valneva commented, "This congress
is a great opportunity for Valneva to present its clinical
portfolio to leading vaccine industry experts and to underline the
strong medical needs which exit for the vaccines that the Company
is currently developing. We are also looking forward to meeting our
current partners and discussing new potential collaborations."
Valneva, a gold sponsor of the event, will have
a display in the exhibit area adjacent to the conference
facilities, at booth number 27.
About Valneva SE
Valneva is a fully integrated, commercial stage
biotech company focused on developing innovative life-saving
vaccines.
The Company seeks financial returns through
focused R&D investments in promising product candidates and
growing financial contributions from commercial products, striving
towards financial self-sustainability.
Valneva's portfolio includes two commercial
vaccines for travelers: IXIARO®/JESPECT® indicated for the
prevention of Japanese encephalitis and DUKORAL® indicated for the
prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has proprietary vaccines in
development including candidates against Clostridium difficile and
Lyme disease. A variety of partnerships with leading pharmaceutical
companies complement the Company's value proposition and include
vaccines being developed using Valneva's innovative and validated
technology platforms (EB66® vaccine production cell line, IC31®
adjuvant).
Valneva is listed on Euronext-Paris and the
Vienna stock exchange and has operations in France, Austria, Great
Britain, Sweden, Canada and the US with over 400 employees. More
information is available at www.valneva.com.
Contact Valneva
SE Laetitia Bachelot-Fontaine Head of Investor Relations &
Corporate Communications T +02-28-07-14-19 M +33 (0)6 4516 7099
investors@valneva.com |
Nina Waibel
Corporate Communications Specialist T +43-1-206 20-1149
communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
[1] Latest data from the CDC (PR on Aug 19, 2013);
[2]
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113294
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/082951d2-3037-4580-898e-c42ffeb0a6c5